Results 151 to 160 of about 56,993 (185)

Potential beneficial role of sevelamer hydrochloride in diabetic retinopathy

Medical Hypotheses, 2013
Patients with chronic kidney disease (CKD) experience co-morbid illnesses, including cardiovascular disease and retinopathy. Sevelamer hydrochloride (Renagel®); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C ...
Drača, Nataša, Lazić, Ratimir, Simić, Petra, Dumić-Čule, Ivo, Luetić Tikvica, Ana, Gabrić, Nikica   +5 more
openaire   +4 more sources

A phosphate binding assay for sevelamer hydrochloride by ion chromatography

Journal of Pharmaceutical and Biomedical Analysis, 1999
Sevelamer hydrochloride is a cross-linked polymeric amine; it is the active ingredient of Renagel capsules. Renagel is indicated for the control of hyperphosphatemia in patients with end-stage renal disease. An in vitro phosphate-binding assay is required to measure the drug's efficacy.
J R, Mazzeo, R M, Peters, M R, Hanus, X, Chen, K A, Norton   +4 more
openaire   +2 more sources

Sevelamer hydrochloride: an effective phosphate binder in dialyzed children

Pediatric Nephrology, 2003
This pilot study was designed to evaluate the efficacy and acceptability of sevelamer hydrochloride as a phosphate binder in pediatric patients treated with dialysis. A 6-month open-label trial of sevelamer hydrochloride (Renagel) was initiated in 17 patients, aged 11.8+/-3.7 years, undergoing hemodialysis ( n=3) or peritoneal dialysis ( n=14 ...
Homa, Mahdavi, Beatriz D, Kuizon, Barbara, Gales, He-Jing, Wang, Robert M, Elashoff, Isidro B, Salusky   +5 more
openaire   +2 more sources

Effect of Sevelamer Hydrochloride on Bone in Experimental Uremic Rats

Therapeutic Apheresis and Dialysis, 2009
Abstract:  Hyperphosphatemia in dialysis patients is known to cause secondary hyperparathyroidism and high‐turnover bone disease. Sevelamer hydrochloride (sevelamer) is a nonabsorbed, calcium‐free phosphate‐binder. We determined the effect of sevelamer on parathyroid hormone (PTH)‐induced high bone turnover.
Michio, Kuwahara, Seiji, Inoshita, Yoshio, Terada, Sei, Sasaki   +3 more
openaire   +2 more sources

Sevelamer Hydrochloride

Drugs, 2008
Sevelamer (Renagel), an orally administered metal-free cationic hydrogel polymer/resin that binds dietary phosphate in the gastrointestinal (GI) tract, is approved for use in the US, Europe and several other countries for the treatment of hyperphosphataemia in adult patients with end-stage renal disease (ESRD) on haemodialysis or peritoneal dialysis ...
David R, Goldsmith, Lesley J, Scott, Risto S, Cvetković, Greg L, Plosker   +3 more
openaire   +2 more sources

Role of Sevelamer Hydrochloride in the Coronary Artery Calcification Score

Therapeutic Apheresis and Dialysis, 2005
Abstract:  The coronary artery calcification score (CACS) is higher in hemodialysis (HD) patients than in non‐HD patients for each age group from the fifth to the eighth decade of life. In order to clarify the relationship between the rate of change in the CACS and several factors related to calcium (Ca) and phosphate (P) metabolism in HD patients, we ...
Yoshinari, Tsuruta, Kana, Kaneshiro, Yukio, Narita, Takaaki, Obayashi, Mikiko, Fujii, Masayasu, Narita, Kanna, Sasai, Takayuki, Yoshimata, Yuzo, Watanabe, Kenji, Maeda   +9 more
openaire   +2 more sources

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis

Clinical Nephrology, 2007
Sevelamer carbonate is an anion exchange resin with the same polymeric structure as sevelamer hydrochloride in which carbonate replaces chloride as the anion. The study investigated the effects of sevelamer carbonate and sevelamer hydrochloride on serum phosphorus, lipids and bicarbonate levels in hemodialysis patients.This was a double-blind ...
J, Delmez, G, Block, J, Robertson, S, Chasan-Taber, A, Blair, M, Dillon, A J, Bleyer   +6 more
openaire   +2 more sources

Impact of Sevelamer Hydrochloride and the K/DOQI Guidelines

Therapeutic Apheresis and Dialysis, 2005
Abstract:  Sevelamer hydrochloride (SH) was registered as a new drug under the Japanese national health insurance scheme in 2003, and the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for the treatment of renal osteodystrophy were released the same year.
openaire   +2 more sources

A Review Article: Sevelamer Hydrochloride and Metabolic Acidosis in Dialysis Patients

Cardiovascular & Hematological Disorders-Drug Targets, 2008
Sevelamer hydrochloride is a phosphate binder and its effectiveness to reduce the cardiovascular mortality of dialysis patients has been tested. Sevelamer hydrochloride also contains chlorine, so a decrease in bicarbonate due to chlorine load was anticipated and metabolic acidosis thought to associate with sevelamer hydrochloride has been reported in ...
Yoshinari, Oka, Masashi, Miyazaki, Shigeko, Takatsu, Toshiaki, Oohara, Keisuke, Toda, Futoshi, Uno, Hiroaki, Matsuda   +6 more
openaire   +2 more sources

Effects of Calcium Carbonate, Sevelamer Hydrochloride or Pantoprazole on the Pharmacokinetics of Cinacalcet

Clinical Drug Investigation, 2014
Secondary hyperparathyroidism is a common consequence of chronic kidney disease. Cinacalcet (Sensipar(®)) is often prescribed in combination to reduce elevated levels of parathyroid hormone, calcium and phosphorus. The objective of this study was to assess the effects of concomitantly administered therapies of calcium carbonate (CaCO(3); TUMS ...
Desmond, Padhi, Robert, Harris, John T, Sullivan   +2 more
openaire   +2 more sources